Daiichi Sankyo’s SANTORINI Study Gets Underway, Investigating Cholesterol Care Across Europe
Retrieved on:
Wednesday, June 10, 2020
The SANTORINI study will provide important insights into how patients are currently being managed and the effectiveness of the treatments they are receiving.
Key Points:
- The SANTORINI study will provide important insights into how patients are currently being managed and the effectiveness of the treatments they are receiving.
- Daiichi Sankyo has been working closely with SANTORINI trial sites to ensure we follow local recommendations to progress the study in the most effective and safest way possible, said Dr. Inaam Haq, Medical Affairs Director, Antithrombotic & Cardiovascular at Daiichi Sankyo Europe.
- The SANTORINI study is a multinational, prospective, observational study that will enrol 8,000 patients from 800 sites in 14 countries across Europe.
- Daiichi Sankyo Europe has licensed exclusive commercialisation rights to these products in the European Economic Area and Switzerland from Esperion.